Practical high resolution microscopy of un-cut, un-embedded lung biopsies

DESCRIPTION (provided by applicant): This aim of this Phase I SBIR proposal from Applikate Technology, LLC, is to validate the use of ClearView, a novel approach to performing complete and non-destructive imaging of tissue specimens, for primary pathologyof lung biopsies. Error rates for diagnoses of lung cancer from biopsies may run as high as 15%. Although the root causes of errors are diverse, immunohistochemistry (IHC) and molecular analysis are some of the newest and most valuable tools employed forsurgical pathology accuracy. Indeed, results from IHC and molecular analysis are now considered critical for determining the path of care and the appropriate agent for chemotherapy. However, their use is dependent on having enough sample tissue after initial morphologic evaluation. Applikate Technologies has developed ClearView, a proprietary approach for morphologic evaluation of biopsies without worry that tissue will be exhausted before IHC and molecular analysis studies. In addition, ClearView en